Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Recordati SpAMIL:REC +0.57%95 Cash-to-Debt is 0.17 as of Jun. 2026, which is 11% below its 10-year median of 0.19. GuruFocus rates MIL:REC with a GF Score™ of 95/100 and a GF Value™ of €61.57 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 984 Drug Manufacturers companies, Recordati SpA ranks worse than 78.66% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Recordati SpA's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.17.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Recordati SpAcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Recordati SpA's Cash-to-Debt or its related term are showing as below:
MIL:REC'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12 Med: 0.19 Max: 0.65
Current: 0.17
During the past 13 years, Recordati SpA's highest Cash to Debt Ratio was 0.65. The lowest was 0.12. And the median was 0.19.
MIL:REC's Cash-to-Debt is ranked worse than 78.66% of 984
companies
in the Drug Manufacturers industry
Industry Median: 0.96
vs MIL:REC: 0.17
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Recordati SpA Cash-to-Debt Related Terms
Recordati SpA Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Recordati SpA's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MIL:REC vs LLY, JNJ, ABBV: Cash-to-Debt Comparison
For the Drug Manufacturers - General subindustry, Recordati SpA's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recordati SpA Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Recordati SpA's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recordati SpA (MIL:REC) has a Cash-to-Debt of 0.17 as of Jun. 2026. This is 11% below median its historical median of 0.19. Over the past decade, Recordati SpA's Cash-to-Debt has ranged from 0.12 to 0.65. According to the industry distribution chart, Recordati SpA ranks #774 out of 984 companies in the Drug Manufacturers industry, placing it in the top 78.7%.
Is Recordati SpA's Cash-to-Debt too high?
Recordati SpA's current Cash-to-Debt of 0.17 is 11% below median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 0.65. The Drug Manufacturers industry median Cash-to-Debt is 0.96. Recordati SpA's value of 0.17 is 82.3% below this industry median. Based on the distribution chart, Recordati SpA ranks #774 out of 984 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Recordati SpA has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Cash-to-Debt compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #774 out of 984 companies for Cash-to-Debt. This places Recordati SpA in the lower half of its industry. The industry median Cash-to-Debt is 0.96. Recordati SpA's value of 0.17 is 82.3% below this benchmark. Historically, Recordati SpA's own Cash-to-Debt has ranged from 0.12 to 0.65 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 0.96, Recordati SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.96, based on 984 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Recordati SpA's current Cash-to-Debt of 0.17 is 82.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Recordati SpA's current Cash-to-Debt is 0.17, which is 11% below median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €61.57, compared to a current price of €52.65 — trading 14.5% below its estimated fair value. The current Cash-to-Debt is 0.17, which is 11% below median its 10-year median of 0.19 and 82.3% below the Drug Manufacturers industry median of 0.96. Recordati SpA's overall GF Score™ is 95/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current Cash-to-Debt is 0.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recordati SpA (MIL:REC) Overvalued in 2026?
Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued.
The current stock price of €52.65 is trading 14.5% below its estimated GF Value™ of €61.57.
GuruFocus considers Recordati SpA to be Modestly Undervalued.
Key valuation signals for MIL:REC:
Cash-to-Debt: 0.17 (11% below median its 10-year median of 0.19)
GF Value™: €61.57 vs. price of €52.65 (14.5% below fair value)
Industry Position: 82.3% below the Drug Manufacturers median (#774 of 984)
No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
95GF Score
Get the complete analysis for MIL:REC
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:REC has been successfully added to your 
